Capsule Summary Slidesets

Share

Program Content

Activities

  • Roxadustat in LR-MDS
    Oral Roxadustat in Anemia Secondary to Lower-Risk MDS: 1-Yr Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • Luspatercept in MF Anemia
    Phase II Study of Luspatercept in RBC Transfusion-Dependent Patients With Myelofibrosis-Associated Anemia: Updated Results
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2020

    Expires: December 17, 2021

  • 5-Yr RopegIFN in PV
    CONTINUATION-PV: 5-Yr Results of Ropeginterferon α-2b in Polycythemia Vera
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2020

    Expires: December 10, 2021

  • Imetelstat in MF
    Correlation of Survival and Other Clinical Benefits With Imetelstat Therapy in High-Risk, JAK Inhibitor–Refractory Myelofibrosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2020

    Expires: December 09, 2021

  • CPI-0610 + RUX in MF
    MANIFEST: Novel BET Inhibitor, CPI-0610, Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis Patients
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2020

    Expires: December 08, 2021

  • Pevonedistat/AZA in Higher-Risk MDS
    Randomized Phase II Study of Pevonedistat Plus Azacitidine vs Azacitidine: Post Hoc Analysis in Higher-Risk MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • DACOTA DEC vs HY in CMML
    DACOTA Phase III Study of Decitabine vs Hydroxyurea for Advanced Proliferative CMML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • HSCT in Older MDS Pts
    BMT CTN 1102: RIC Allogeneic HSCT vs Non-HSCT Therapy in Patients 50-75 Yrs With Higher-risk MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2020

    Expires: December 09, 2021

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology